Verve Therapeutics’ Stock Falls 40% as Analysts Question Safety of Cholesterol-Cutting Gene-Editing Treatment
Verve Therapeutics Inc. shares fell 40% after releasing early-stage clinical trial data on its gene-editing treatment for high cholesterol....